FRONTEO and Maruishi Pharmaceutical Launch Co-Creation Project for Biomarker Discovery Using Drug Discovery AI Factory
Accelerating research and development of prescription drugs through proprietary technology that systematically discovers unknown associations between diseases and molecules from known literature information
FRONTEO Inc. and Maruishi Pharmaceutical Co., Ltd. are pleased to announce that they will commence a co-creation project to discover biomarkers (*1) in the field of life science AI (AI drug discovery).
In clinical trials for drug development, the use of biomarkers, which play an important role in determining the mechanism of action and therapeutic effects of drugs, has been shown to provide excellent safety and good efficacy outcomes (1). In this co-creation project, we will combine FRONTEO’s AI drug discovery support service “FRONTEO Drug Discovery AI Factory” (DDAIF) (*2), which specializes in hypothesis generation, with Maruishi Pharmaceutical’s accumulated knowledge and technology in drug research and development to find appropriate biomarkers, thereby accelerating Maruishi Pharmaceutical’s drug research and development.
Maruishi Pharmaceutical’s main targets are the fields of perioperative, acute and emergency medical care, infection control, and supportive medical care (cancer supportive care), and in order to meet unmet medical needs (*3) including surrounding areas, the company is engaged in integrated research and development activities, including the search for R&D seeds, basic drug discovery research, formulation design, CMC (*4) related tests, non-clinical trials, clinical trials, and even post-marketing drug development.
FRONTEO will utilize its proprietary, specialized AI “KIBIT” natural language processing technology (patented) in co-creation projects with multiple pharmaceutical companies to improve the success rate of drug development for client companies and contribute to people’s health.
SOURCE: NIKKEI
